|
KMID : 1146920230530020213
|
|
Journal of Pharmaceutical Investigation
2023 Volume.53 No. 2 p.213 ~ p.233
|
|
|
Nanomedicine approaches for medulloblastoma therapy
|
|
Lim Chae-Min
Koo Ja-In
Oh Kyung-Taek
|
|
|
Abstract
|
|
|
Background : Over the past 30 years, brain tumors have been intensively studied with a variety of therapeutic approaches. However, brain cancer is still one of the most lethal forms of cancer, and the mortality rates have still not significantly improved. Since the late 2010s, transcriptomic analysis of medulloblastoma (MB), the most malignant pediatric brain tumor, has been actively conducted. These efforts have facilitated classification of MB into specific subgroups, enabling more molecularly targeted therapies. However, from a pharmaceutical standpoint, there is one more hurdle to overcome, which is the blood-brain barrier (BBB).
Area Covered : In this review, we provide information on the characteristics of each subgroup of MB and a list of Food and Drug Administration (FDA)-approved drugs or drugs in clinical trials used for the treatment of this disease. In addition, we introduce lists of methods that can overcome the BBB, a major hurdle for MB treatment, by applying nanotechnology. Finally, we provide a general overview of the state of nanomedicine for brain tumors.
Expert Opinion : Various types of nanotechnologies have been extensively studied and have shown clear advantages for treatment of brain tumors. However, despite the exploration of these various nanoparticles in preclinical studies, the types of nanoparticles evaluated in clinical trials are very limited, and a number of clinical trial failures have also occurred. Therefore, further insights into relevant regulations as well as rational design of nanoparticles for improved reproducibility are required to bridge the gap between preclinical and clinical studies.
|
|
|
KEYWORD
|
|
|
Medulloblastoma, Brain tumor, Nanomedicine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|